Top-Rated StocksTop-RatedNASDAQ:EXAS Exact Sciences (EXAS) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free EXAS Stock Alerts $59.42 +0.63 (+1.07%) (As of 01:46 PM ET) Add Compare Share Share Today's Range$58.85▼$60.3150-Day Range$56.27▼$74.2652-Week Range$56.05▼$100.77Volume943,336 shsAverage Volume2.27 million shsMarket Capitalization$10.79 billionP/E RatioN/ADividend YieldN/APrice Target$97.44 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Exact Sciences alerts: Email Address Exact Sciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside63.2% Upside$97.44 Price TargetShort InterestBearish5.45% of Shares Sold ShortDividend StrengthN/ASustainability-0.83Upright™ Environmental ScoreNews Sentiment1.01Based on 5 Articles This WeekInsider TradingSelling Shares$4.17 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.86) to $0.02 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.93 out of 5 starsMedical Sector186th out of 908 stocksMedical Laboratories Industry7th out of 19 stocks 3.4 Analyst's Opinion Consensus RatingExact Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 12 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageExact Sciences has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.45% of the outstanding shares of Exact Sciences have been sold short.Short Interest Ratio / Days to CoverExact Sciences has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Exact Sciences has recently increased by 55.99%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldExact Sciences does not currently pay a dividend.Dividend GrowthExact Sciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreExact Sciences has received a 74.50% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private genetic testing services", "Biochemical assay kits for colorectal cancer diagnostics", and "Biochemical assay kits for liver cancer diagnostics" products. See details.Environmental SustainabilityThe Environmental Impact score for Exact Sciences is -0.83. Previous Next 2.2 News and Social Media Coverage News SentimentExact Sciences has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Exact Sciences this week, compared to 7 articles on an average week.Search InterestOnly 27 people have searched for EXAS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 16 people have added Exact Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -24% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exact Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,165,273.00 in company stock.Percentage Held by InsidersOnly 1.30% of the stock of Exact Sciences is held by insiders.Percentage Held by Institutions88.82% of the stock of Exact Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Exact Sciences are expected to grow in the coming year, from ($0.86) to $0.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exact Sciences is -52.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exact Sciences is -52.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExact Sciences has a P/B Ratio of 3.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIWhat is the 72-Hour Profit Surge?One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…Click here now to get all the details. About Exact Sciences Stock (NASDAQ:EXAS)Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Read More EXAS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EXAS Stock News HeadlinesApril 4, 2024 | insidertrades.comExact Sciences Co. (NASDAQ:EXAS) EVP Sells $140,000.00 in StockApril 24, 2024 | finance.yahoo.comHere’s Why Baron Health Care Fund Reduced Exact Sciences Corporation (EXAS)April 26, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 19, 2024 | americanbankingnews.comExact Sciences (NASDAQ:EXAS) Shares Gap Up to $63.86April 17, 2024 | finance.yahoo.comExact Sciences Corporation's (NASDAQ:EXAS) Profit OutlookApril 17, 2024 | americanbankingnews.comExact Sciences Sees Unusually Large Options Volume (NASDAQ:EXAS)April 15, 2024 | markets.businessinsider.comExact Sciences Appoints Aaron Bloomer As Chief Financial OfficerApril 15, 2024 | businesswire.comExact Sciences Names Aaron Bloomer as New Chief Financial OfficerApril 26, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 12, 2024 | finance.yahoo.comHere’s Why Exact Sciences Corporation (EXAS) Declined in Q1April 11, 2024 | businesswire.comExact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior NotesApril 10, 2024 | finance.yahoo.comExact Sciences (EXAS) Stock Moves -0.89%: What You Should KnowApril 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Exact Sciences on Promising Multi-Cancer Detection TechnologyApril 8, 2024 | forbes.comHow This CEO Consumerized Cancer Diagnostics Into A $13B EnterpriseApril 8, 2024 | businesswire.comExact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024April 8, 2024 | finance.yahoo.comSorry, but Blood Tests Won’t Replace Stool Samples or Colonoscopies YetApril 8, 2024 | businesswire.comExact Sciences Schedules First Quarter 2024 Earnings CallApril 5, 2024 | investorplace.comThe 3 Best Cathie Wood Stocks to Buy in April 2024April 4, 2024 | fool.com1 Beaten-Down Cathie Wood Stock to Buy and HoldApril 4, 2024 | businesswire.comExact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform TreatmentApril 2, 2024 | benzinga.comExact Sciences's Options Frenzy: What You Need to KnowApril 2, 2024 | seekingalpha.comExact Sciences: Cancer Battle Continues, Shares Likely To PlateauApril 2, 2024 | finance.yahoo.comExact Sciences, A Cathie Wood Stock, Surges As Rival Colon Cancer Test PalesMarch 28, 2024 | msn.comExact Sciences gains after data for novel cancer screening testMarch 28, 2024 | businesswire.comExact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-CancerMarch 27, 2024 | finance.yahoo.comExact Sciences Named 2024 Gallup Exceptional Workplace Award WinnerMarch 26, 2024 | investorplace.com3 Growth Stocks to Buy at 52-Week Lows in MarchSee More Headlines Receive EXAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2024Today4/26/2024Next Earnings (Confirmed)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryBiotechnology Current SymbolNASDAQ:EXAS CUSIP30063P10 CIK1124140 Webwww.exactsciences.com Phone(608) 284-5700Fax608-284-5701Employees6,600Year Founded1995Price Target and Rating Average Stock Price Target$97.44 High Stock Price Target$121.00 Low Stock Price Target$73.00 Potential Upside/Downside+65.7%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($1.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-204,150,000.00 Net Margins-8.17% Pretax Margin-8.07% Return on Equity-6.60% Return on Assets-3.20% Debt Debt-to-Equity Ratio0.74 Current Ratio2.32 Quick Ratio2.07 Sales & Book Value Annual Sales$2.50 billion Price / Sales4.27 Cash Flow$0.02 per share Price / Cash Flow3,730.32 Book Value$17.39 per share Price / Book3.38Miscellaneous Outstanding Shares181,530,000Free Float179,171,000Market Cap$10.67 billion OptionableOptionable Beta1.25 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Kevin T. Conroy (Age 58)Chairman of The Board & CEO Comp: $1.54MMr. Jeffrey T. Elliott CFA (Age 46)EVP & CFO Comp: $518.13kMs. Sarah Condella (Age 43)Executive Vice President of Human Resources Comp: $742.76kMr. Everett V. Cunningham (Age 58)Chief Commercial Officer Comp: $1.34MDr. Jorge A. Garces Ph.D. (Age 52)Chief Science Officer Mr. Nassar NizamiChief Information OfficerMs. Megan JonesAssociate Manager of Investor RelationsMr. Tim CaprezChief Compliance Counsel & VPMr. James Herriott (Age 44)Senior VP, General Counsel & Secretary Mr. Vic ParkerHead of SalesMore ExecutivesKey CompetitorsNateraNASDAQ:NTRAPRA Health SciencesNASDAQ:PRAHExelixisNASDAQ:EXELPPDNASDAQ:PPDLaboratory Co. of AmericaNYSE:LHView All CompetitorsInsiders & InstitutionsSimplex Trading LLCBought 140,100 shares on 4/25/2024Ownership: 0.000%Fjarde AP Fonden Fourth Swedish National Pension FundBought 2,100 shares on 4/25/2024Ownership: 0.031%IMA Wealth Inc.Sold 1,105 shares on 4/25/2024Ownership: 0.018%WCM Investment Management LLCBought 1,195 shares on 4/25/2024Ownership: 0.007%Assenagon Asset Management S.A.Sold 1,167 shares on 4/24/2024Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions EXAS Stock Analysis - Frequently Asked Questions Should I buy or sell Exact Sciences stock right now? 14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EXAS shares. View EXAS analyst ratings or view top-rated stocks. What is Exact Sciences' stock price target for 2024? 14 brokerages have issued 12-month target prices for Exact Sciences' shares. Their EXAS share price targets range from $73.00 to $121.00. On average, they predict the company's share price to reach $97.44 in the next twelve months. This suggests a possible upside of 63.2% from the stock's current price. View analysts price targets for EXAS or view top-rated stocks among Wall Street analysts. How have EXAS shares performed in 2024? Exact Sciences' stock was trading at $73.98 at the beginning of 2024. Since then, EXAS shares have decreased by 19.3% and is now trading at $59.72. View the best growth stocks for 2024 here. Are investors shorting Exact Sciences? Exact Sciences saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 9,890,000 shares, an increase of 56.0% from the March 31st total of 6,340,000 shares. Based on an average trading volume of 2,390,000 shares, the short-interest ratio is currently 4.1 days. View Exact Sciences' Short Interest. When is Exact Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our EXAS earnings forecast. How can I listen to Exact Sciences' earnings call? Exact Sciences will be holding an earnings conference call on Wednesday, May 8th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link. How were Exact Sciences' earnings last quarter? Exact Sciences Co. (NASDAQ:EXAS) issued its quarterly earnings results on Wednesday, February, 21st. The medical research company reported ($0.27) EPS for the quarter, beating analysts' consensus estimates of ($0.53) by $0.26. The medical research company had revenue of $646.89 million for the quarter, compared to the consensus estimate of $638.83 million. Exact Sciences had a negative trailing twelve-month return on equity of 6.60% and a negative net margin of 8.17%. The firm's revenue was up 17.0% compared to the same quarter last year. During the same period last year, the business posted ($0.72) EPS. What ETFs hold Exact Sciences' stock? ETFs with the largest weight of Exact Sciences (NASDAQ:EXAS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Simplify Health Care ETF (PINK), First Trust NYSE Arca Biotechnology Index Fund (FBT), Tema Oncology ETF (CANC), Fidelity Disruptive Medicine ETF (FMED), Principal Healthcare Innovators ETF (BTEC) and VanEck Biotech ETF (BBH). What guidance has Exact Sciences issued on next quarter's earnings? Exact Sciences updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.8 billion. What is Kevin T. Conroy's approval rating as Exact Sciences' CEO? 328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 69.0% of employees surveyed would recommend working at Exact Sciences to a friend. What other stocks do shareholders of Exact Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL), Block (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV). Who are Exact Sciences' major shareholders? Exact Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (1.09%), Allspring Global Investments Holdings LLC (0.28%), Wasatch Advisors LP (0.16%), Simplex Trading LLC (0.00%), Global Assets Advisory LLC (0.14%) and Factory Mutual Insurance Co. (0.10%). Insiders that own company stock include Brian Baranick, Canada Pension Plan Investment, D Scott Coward, Daniel J Levangie, Everett Cunningham, Jacob A Orville, James Edward Doyle, James Herriott, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy and Sarah Condella. View institutional ownership trends. How do I buy shares of Exact Sciences? Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Exact Sciences have any subsidiaries? The following companies are subsidiares of Exact Sciences: Armune BioScience, Ashion Analytics, Base Genomics Limited, Biomatrica Inc., Exact Sciences Development Company LLC, Exact Sciences Laboratories LLC, Genomic Health Inc., Genomic Health International Holdings LLC, Paradigm Diagnostics Inc., Sampleminded Inc., Thrive Earlier Detection Corporation, and Viomics Inc..Read More This page (NASDAQ:EXAS) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss RatingsBiden out June 13; Kamala won’t replace him?Paradigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
